Aridis Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

Aridis Pharmaceuticals

27/03/2023 21:37

* Aridis Pharmaceuticals Inc  ARDS.OQ   ARDS.O  is expected
to show a fall in quarterly revenue when it reports  results on
March 29 (estimated). 
    * The Los Gatos California-based  company is expected to
report  a
45.9% decrease in revenue to $308.33 thousand from $570 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aridis
Pharmaceuticals
Inc is for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $6​, above​ its last closing price
of $0.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.34       -0.17      -0.47     Missed  -176.5
 Jun. 30 2022  -0.08       -0.06      -0.45     Missed  -650
 Mar. 31 2022  -0.51       -0.51      -0.44     Beat    13.7​
 Dec. 31 2021  -0.51       -0.41      -0.92     Missed  -124.4
 ​​Sep.        -0.51       -0.51      -1.94     Missed  -277.9
 30 2021                                                
 Jun. 30 2021  -0.64       -0.63      -0.55     Beat    12.4​
 Mar. 31 2021  -0.61       -0.62      -0.77     Missed  -24.7
 Dec. 31 2020              -0.59      -0.59     Met     0.6
 This summary was machine generated March 27 at 20:37 GMT.  All
figures in US dollars  unless otherwise stated